As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include an interesting publication on pediatric CML and papers from low- and middle-income countries.

Read Professor Hughes' CML publications of the month: December 2024

Clinical CML papers

• Asciminib in newly diagnosed chronic myeloid leukemia. Reply.
  Hochhaus A et al. N Engl J Med, December 2024
• Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study
  Hughes TP et al. J Hematol Oncol, December 2024 – open access publication
• The effect of body mass index on the safety of bosutinib in patients with chronic myeloid leukemia: A post hoc pooled data analysis
  Isfort S et al. Leuk Res, December 2024
• Advanced-stage chronic myeloid leukemia: Options for difficult treatment situations – Review
  Atallah E and Deininger M. Drugs, December 2024 (epub ahead of print)
• Novel treatment strategies for chronic myeloid leukemia
  Cruz-Rodriguez N and Deininger M. Blood, December 2024 (epub ahead of print)
• Mutation of epigenetic regulators at diagnosis is an independent predictor of tyrosine kinase inhibitor treatment failure in chronic myeloid leukemia: A Report from the RESIDIAG Study
  Guerineau H et al. Am J Hematol, December 2024 (epub ahead of print) – open access publication
• Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia
  Yang Y et al. Haematologica, December 2024 – open access publication
• Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) - Review
  Lagana A. at al. Expert Rev Hematol, December 2024 (epub ahead of print)
• Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients
  Clark SE et al. J Oncol Pharm Pract, December 2024
• Is there really an accelerated phase of chronic myeloid leukemia at presentation?
  Yang S et al. Leukemia, December 2024 (epub ahead of print) – open access publication

Scientific CML papers

• Correlation analysis of bone marrow microvessel density and miRNA expression on drug resistance in patients with chronic myeloid leukemia after tyrosine kinase inhibitor treatment
  Guo YG et al. Hematology, December 2024 – open access publication
• BCR::ABL1-induced mitochondrial morphological alterations as a potential clinical biomarker in chronic myeloid leukemia
  Suzuki K et al. Cancer Si, December 2024 – open access publication

Pediatric papers

• Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
  Shima H et al. Leukemia, December 2024 (epub ahead of print)

LMIC CML papers

• Early molecular response to imatinib first-line therapy and predictive factors of poor outcomes for chronic myeloid leukemia patients in Cote d’Ivoire
  Koffi KG et al. Adv Hematol, December 2024 – open access publication
• Influence of CYP2C8*3and ABCG2C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia
  Mongoura SA et al. Cancer Chemother Pharmacol, December 2024 – open access publication
  
  

Read Professor Hughes' summaries of key CML publications

This series of paper summaries is an extension of Professor Tim Hughes' 'CML publications of the month' news service.
These summaries, selected and curated by Professor Hughes, will be compiled and provided every three months, offering a comprehensive overview of key CML papers. This approach ensures that clinicians, researchers, and healthcare professionals stay up-to-date with important pivotal studies and emerging trends in CML research.

CML paper summary #3 - January 2025: 
The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib
Link to full paper (Leukemia 2024 Sep;38(9):2041-2045)

This study published in Leukemia investigates the potential resistance of specific BCR::ABL1 isoforms to asciminib, particularly focusing on the e13a3 (b2a3) and e14a3 (b3a3) isoforms.

View the paper summary here

Read more